Lupin Ltd’s Pithampur unit 2 manufacturing facility located in Indore has been cleared by Health Canada after a review.
“Following the review, Health Canada has maintained the compliant rating for unit 2 at Pithampur (Indore) and has issued a revised ‘Establishment Licence’,” Lupin said in a BSE filing today.
In November 2017, Lupin had received a warning letter from the US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore. Shares of Lupin were trading up by 3.6 per cent at Rs 762.90 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.